A clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors
viferaxs.com · LinkedIn · Tübingen, Germany · Healthtech · Founded 2022 · 2-10 people
LATEST ROUND
Series A
$13.7M · 2026-09-23
TOTAL RAISED · USD
$13.7M
across 1 round
INVESTORS
2
no lead named
SOURCES
1
from 1 publisher
Rounds
[ 1 ]
Series A
$13.7M · 2026-09-23
Published on thinner evidence, 1 source1 outlet. #88 in Trending
lead not stated
[ NOT YET VERIFIED ]0.75
Published on thinner evidence: weigh the verdict and its sources before you rely on it.
[ BUILT WITH ]·[ SEARCH ]found on a watched publisher·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]not yet read back·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]dossier built by the Firecrawl agent
Round
Amount
Announced
Lead
Buzz
Series A
Published on thinner evidence, 1 source
$13.7M
€12 million
2026-09-23
not stated
1 outlet. #88 in Trending
[ NOT YET VERIFIED ]0.75
Published on thinner evidence: weigh the verdict and its sources before you rely on it.
[ BUILT WITH ]·[ ]
Dossier
[ CHECKED ]
Fetched today
ViferaXS develops off-the-shelf peptide-based cancer immunotherapies that activate T cells against tumor antigens for patients with blood cancers and solid tumors.
Founders
Prof. Hans-Georg Rammensee · Co-Founder and Immunologist
He is a leading immunologist and cancer immunotherapy researcher at the University of Tübingen whose work covers MHC molecules, tumor-specific peptides and personalized cancer vaccines.
Prof. Dr. Juliane Walz · Co-Founder and Immunologist / Oncologist
She is a physician trained in hematology and oncology and is Head of Peptide-based Immunotherapy and Medical Director of the Clinical Cooperation Unit for Translational Immunology at University Hospital Tübingen.
Headcount
2-10 people
Total raised
up to €12 million, including grant funding
Backers
SPRIND, the German Federal Agency for Breakthrough Innovation
WHY IT MATTERS
ViferaXS is taking CLLTAXS01 into a randomized Phase II trial after a Phase I study reported T-cell responses in 19 of 20 patients. Its up-to-€12 million Series A, led by SPRIND and Huma, funds the CLL trial, ongoing AML and FLC Phase I programs, team growth and further preclinical work, making the financing a test of whether the immune signal can translate into patient benefit.
ViferaXS sells peptide-based cancer immunotherapy solutions for hematologic malignancies and solid tumors to biopharmaceutical partners and healthcare providers.
Founded
2022
Headcount
2
Type
Privately Held
Industry
Biotechnology Research
Via Alexandria from FullEnrich: founded, headcount, type, industry
